CERo Therapeutics Holdings, Inc. Common Stock (CERO)
Official siteHEALTHCARE • BIOTECHNOLOGY • PINK
Market Cap: $358,150
Last updated: Nov 13, 2026 at 4:00 PM ET
CERo Therapeutics Holdings, Inc. Common Stock (CERO) Financials: Revenue, Profit and Cash Flow
CERo Therapeutics Holdings, Inc. Common Stock reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$19.92M and operating cash flow was -$16.10M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of $4.02M.
Revenue and Margins
The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $18.46M.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $0 | N/A | N/A | N/A | N/A |
| Dec 2024 | N/A | N/A | N/A | N/A | N/A |
| Dec 2023 | $0 | N/A | N/A | N/A | N/A |
| Dec 2022 | $0 | N/A | N/A | N/A | N/A |
| Dec 2021 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Cost of revenue | $0 | $1.16M | $0 | $0 | N/A |
| Gross profit | $0 | -$1.16M | $0 | $0 | N/A |
| Research and development | $10.38M | $6.32M | $5.29M | $64.05K | $9.14M |
| Operating income | -$18.46M | -$15.30M | -$7.68M | -$2.91M | -$332.03K |
| Net income | -$19.92M | -$7.73M | -$7.29M | -$667.74K | -$315.55K |
| EBITDA | -$18.24M | -$6.57M | -$6.25M | -$2.91M | -$332.03K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit | $0 | $0 | $0 | N/A | $0 | $0 | $0 | $0 | $0 | -$288.16K | -$284.75K | $0 |
| Operating income | -$3.19M | -$3.85M | -$4.85M | -$4.43M | -$4.36M | -$4.72M | -$4.95M | -$4.40M | -$5.15M | -$4.55M | -$1.29M | -$1.54M |
| Net income | $4.02M | -$1.03M | -$5.89M | -$4.54M | -$4.86M | -$5.42M | -$5.11M | -$4.23M | -$2.45M | -$2.30M | -$1.41M | -$1.35M |
Balance Sheet
As of Dec 2025, the balance sheet showed $1.66M in cash and equivalents and no debt. Shareholder equity was negative, at -$5.45M, as total liabilities of $9.09M exceeded total assets of $3.64M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total assets | $3.64M | $6.21M | $5.13M | $42.37M | $180.08M |
| Current assets | $2.73M | $3.71M | $1.97M | $42.37M | $1.36M |
| Cash and equivalents | $1.66M | $3.33M | $1.60M | $475.87K | $1.10M |
| Total liabilities | $9.09M | $8.10M | $5.08M | $39.90M | $9.25M |
| Short-term debt | $0 | N/A | $599.69K | $650.00K | N/A |
| Shareholder equity | -$5.45M | -$1.89M | -$42.06M | -$11.00M | -$7.67M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.83M | $1.90M | $2.21M | $3.64M | $3.91M | $6.20M | $7.99M | $6.21M | $6.49M | $7.37M | $9.05M | $8.56M |
| Total liabilities | $20.67M | $32.41M | $11.46M | $9.09M | $8.45M | $7.84M | $8.32M | $8.10M | $10.19M | $9.85M | $13.03M | $14.32M |
| Cash and equivalents | $530.68K | $937.51K | $857.49K | $1.66M | $2.02M | $3.30M | $5.20M | $3.33M | $3.38M | $3.65M | $4.59M | $96.87K |
| Shareholder equity | -$18.84M | -$30.51M | -$9.26M | -$5.45M | -$4.54M | -$1.63M | -$329.39K | -$1.89M | -$3.70M | -$2.48M | -$3.98M | -$5.76M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$16.10M | -$5.79M | -$5.79M | -$1.09M | -$697.11K |
| Capital expenditures | N/A | $1 | $3 | $694.23K | $612.57K |
| Free cash flow | N/A | -$5.79M | -$5.79M | -$1.79M | -$1.31M |
| Share repurchases | $500.42K | N/A | N/A | $139.35M | N/A |
| Investing cash flow | $500.00K | N/A | $0 | $180.84M | -$178.50M |
| Financing cash flow | $13.92M | $571.68K | $571.68K | -$138.70M | $180.30M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.03M | -$7.89M | $2.80M | -$3.83M | -$3.21M | -$4.62M | -$4.45M | -$2.76M | -$3.54M | -$5.08M | -$960.77K | -$1.32M |
| Capital expenditures | N/A | N/A | N/A | N/A | $0 | $0 | $4 | $0 | $4 | $2 | $0 | $0 |
| Free cash flow | N/A | N/A | N/A | N/A | -$3.21M | -$4.62M | -$4.45M | -$2.76M | -$3.54M | -$5.08M | -$960.77K | -$1.32M |
Frequently Asked Questions About CERO
What is CERo Therapeutics Holdings, Inc. Common Stock's annual revenue?
CERo Therapeutics Holdings, Inc. Common Stock reported revenue of $0 for the fiscal year ended Dec 31, 2025.
Is CERo Therapeutics Holdings, Inc. Common Stock profitable?
No. CERo Therapeutics Holdings, Inc. Common Stock reported net income of -$19.92M for the fiscal year ended Dec 31, 2025.
How much debt does CERo Therapeutics Holdings, Inc. Common Stock have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $0, short-term debt of $0 and cash and equivalents of $1.66M.
CERO pages: Overview, Financials